Despite public health efforts to reduce the health burden of cigarettes by encouraging smoking cessation, a proportion of smokers remain unwilling to quit. A shift from smoking cessation to tobacco harm reduction, based on smokers switching completely to potentially less harmful products such as electronic cigarettes (ECs), has been proposed as an alternative strategy. This is a single-centre, cross-sectional confinement study, involving healthy exclusive Vuse EC users and current, former, or never-smokers. Exclusive EC use and smoking status will be confirmed by urinary cotinine and exhaled carbon monoxide levels. Participants will be confined for 24 hours, during which they will use their usual product (EC or cigarette) as normal. Biomarkers of exposure and potential harm will be analysed in 24-hour urine and blood and compliance will be measured using N-(2-cyanoethyl)valine. The primary objective is to quantitatively assess differences between EC users and current smokers in urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and 8-epi-prostaglandin F2α Type III, exhaled nitric oxide, and carboxyhaemoglobin, white blood cell count, soluble intercellular adhesion molecule-1, and high-density lipoprotein. Secondary objectives are to quantitatively assess differences between EC users and current smokers in selected urinary biomarkers of tobacco exposure, 11-dehydrothromboxane B2, forced expiratory volume in 1 second as a percentage of predicted, carotid intima-media thickness and a quality of life questionnaire. Endpoints will also be compared between EC users and former and never-smokers. The results of this study are anticipated to add to the current knowledge about the role of ECs in tobacco harm reduction.
| Published in | Journal of Health and Environmental Research (Volume 8, Issue 2) |
| DOI | 10.11648/j.jher.20220802.17 |
| Page(s) | 116-127 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Biomarkers of Exposures, Biomarkers of Potential Harm, Electronic Cigarettes, Tobacco Harm Reduction
| [1] | US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General. Altana (GA); 2014. |
| [2] | Institute of Medicine (US). Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Washington (DC): National Academies Press 2001. |
| [3] | IARC Monographs on the Evalualtion of Carcinogenic Risks to Humans. Smokeless tobacco and some tobacco-specific N-nitrosamines. 2007; 89: 1-592. |
| [4] | Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994; 309 (6959): 901-11. DOI: 10.1136/bmj.309.6959.901. |
| [5] | Popa C. Infrared spectroscopy study of the influence of inhaled vapors/smoke produced by cigarettes of active smokers. J Biomed Opt. 2015; 20 (5): 051003. DOI: 10.1117/1.JBO.20.5.051003. |
| [6] | Rehan HS, Maini J, Hungin APS. Vaping versus Smoking: A Quest for Efficacy and Safety of E-cigarette. Curr Drug Saf. 2018; 13 (2): 92-101. DOI: 10.2174/1574886313666180227110556. |
| [7] | Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: The science base for tobacco harm reduction - Executive summary. Tob Control. 2001; 10 (2): 189-95. DOI: 10.1136/tc.10.2.189. |
| [8] | WHO. WHO Report on the Global Tobacco Epidemic 2011; Warning about the dangers of tobacco. Geneva: World Health Organization; 2011. |
| [9] | WHO report on the global tobacco epidemic 2021: Addressing new and emerging products. 2021. |
| [10] | Perfetti T, Rodgman A. The Complexity of Tobacco and Tobacco Smoke. Beitr Tab Int/Contrib Tob Res. 2011; 24: 215-32. DOI: 10.2478/cttr-2013-0902. |
| [11] | Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control. 2003; 12 (4): 424-30. DOI: 10.1136/tc.12.4.424. |
| [12] | Fearon IM, Phillips G, Carr T, Taylor M, Breheny D, Faux SP. The Role of Oxidative Stress in Smoking-Related Diseases. Mini-Rev Org Chem. 2011; 8 (4): 360-71. DOI: 10.2174/157019311797440317. |
| [13] | US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. 2010. Report No.: QV137H8472010. |
| [14] | Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction. 2016. |
| [15] | National Academies of Sciences Engineering Medicine; Health Medicine Division, Board on Population Health and Public Health Practice. In: Eaton DL, Kwan LY, Stratton K, editors. Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems Public Health Consequences of E-Cigarettes, Washington (DC): National Academies Press (US); 2018. |
| [16] | McNeill A, Brose L, Calder R, Bauld L, Robson D. Vaping in England: an evidence update including mental health and pregnancy 2020 [Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/869401/Vaping_in_England_evidence_update_March_2020.pdf. |
| [17] | Lopez AA, Eissenberg T. Science and the evolving electronic cigarette. Prev Med. 2015; 80: 101-6. DOI: 10.1016/j.ypmed.2015.07.006. |
| [18] | Tayyarah R, Long GA. Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. Regul Toxicol Pharmacol. 2014; 70 (3): 704-10. DOI: 10.1016/j.yrtph.2014.10.010. |
| [19] | Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014; 23 (2): 133-9. DOI: 10.1136/tobaccocontrol-2012-050859. |
| [20] | Nicol J, Fraser R, Walker L, Liu C, Murphy J, Proctor CJ. Comprehensive Chemical Characterization of the Aerosol Emissions of a Vaping Product Based on a New Technology. Chem Res Toxicol. 2020; 33 (3): 789-99. DOI: 10.1021/acs.chemrestox.9b00442. |
| [21] | Margham J, McAdam K, Forster M, Liu C, Wright C, Mariner D, et al. Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke. Chem Res Toxicol. 2016; 29 (10): 1662-78. DOI: 10.1021/acs.chemrestox.6b00188. |
| [22] | Farsalinos KE, Gillman G. Carbonyl Emissions in E-cigarette Aerosol: A Systematic Review and Methodological Considerations. Front Physiol. 2017; 8: 1119. DOI: 10.3389/fphys.2017.01119. |
| [23] | Cunningham A, McAdam K, Thissen J, Digard H. The Evolving E-cigarette: Comparative Chemical Analyses of E-cigarette Vapor and Cigarette Smoke. Front Toxicol. 2020; 2. DOI: 10.3389/ftox.2020.586674. |
| [24] | McNeill A, Brose L, Calder R, Hitchman S. E-cigarettes: an evidence update. A report commissioned by Public Health England. London; 2015. |
| [25] | McRobbie H, Phillips A, Goniewicz ML, Smith KM, Knight-West O, Przulj D, et al. Effects of Switching to Electronic Cigarettes with and without Concurrent Smoking on Exposure to Nicotine, Carbon Monoxide, and Acrolein. Cancer Prev Res (Phila). 2015; 8 (9): 873-8. DOI: 10.1158/1940-6207.Capr-15-0058. |
| [26] | Brose LS, Hitchman SC, Brown J, West R, McNeill A. Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction. 2015; 110 (7): 1160-8. DOI: 10.1111/add.12917. |
| [27] | Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction. 2014; 109 (9): 1531-40. DOI: 10.1111/add.12623. |
| [28] | Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, et al. Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med. 2017; 166 (6): 390-400. DOI: 10.7326/M16-1107. |
| [29] | Cancer Research UK. E-cigarettes Safer than Smoking Says Long-term Study 2017 [Available from: https://news.cancerresearchuk.org/2017/02/06/e-cigarettes-safer-than-smoking-says-long-term-study/. |
| [30] | Murphy J, Gaca M, Lowe F, Minet E, Breheny D, Prasad K, et al. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette. Regul Toxicol Pharmacol. 2017; 90: 342-57. DOI: 10.1016/j.yrtph.2017.09.008. |
| [31] | WHO Study Group on Tobacco Regulation. Report on the Scientific Basis of Tobacco Product Regulation: Fifth Report of a WHO Study Group. 2015. |
| [32] | Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992; 70 (19): 3H-9H. DOI: 10.1016/0002-9149(92)91083-g. |
| [33] | Emerging Risk Factors C, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302 (18): 1993-2000. DOI: 10.1001/jama.2009.1619. |
| [34] | Charland SL, Malone DC. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Curr Med Res Opin. 2010; 26 (2): 365-75. DOI: 10.1185/03007990903484802. |
| [35] | Soria-Florido MT, Schroder H, Grau M, Fito M, Lassale C. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis. 2020; 302: 36-42. DOI: 10.1016/j.atherosclerosis.2020.04.015. |
| [36] | Ridker P, Hennekens C, Roitman-Johnson B, Stampfer M, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998; 351: 88-92. DOI: 10.1016/S0140-6736(97)09032-6. |
| [37] | Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342 (12): 836-43. DOI: 10.1056/NEJM200003233421202. |
| [38] | Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Jr., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997; 96 (12): 4219-25. DOI: 10.1161/01.cir.96.12.4219. |
| [39] | Wu KK, Aleksic N, Ballantyne C, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003; 107: 1729-32. DOI: 10.1161/01.CIR.0000064894.97094.4F. |
| [40] | Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001; 358 (9286): 971-6. DOI: 10.1016/S0140-6736(01)06104-9. |
| [41] | Ludicke F, Ansari SM, Lama N, Blanc N, Bosilkovska M, Donelli A, et al. Effects of Switching to a Heat-Not-Burn Tobacco Product on Biologically Relevant Biomarkers to Assess a Candidate Modified Risk Tobacco Product: A Randomized Trial. Cancer Epidemiol Biomarkers Prev. 2019; 28 (11): 1934-43. DOI: 10.1158/1055-9965.EPI-18-0915. |
| [42] | Hedblad B, Engström G, Janzon E, Berglund G, Janzon L. COHb% as a marker of cardiovascular risk in never smokers: results from a population-based cohort study. Scand J Public Health. 2006; 34 (6): 609-15. DOI: 10.1080/14034940600590523. |
| [43] | Hedblad B, Ogren M, Engström G, Wollmer P, Janzon L. Heterogeneity of cardiovascular risk among smokers is related to degree of carbon monoxide exposure. Atherosclerosis. 2005; 179 (1): 177-83. DOI: 10.1016/j.atherosclerosis.2004.10.005. |
| [44] | Lind P, Engström G, Stavenow L, Janzon L, Lindgärde F, Hedblad B. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol. 2004; 24 (3): 577-82. DOI: 10.1161/01.Atv.0000116863.37311.82. |
| [45] | Calapai G, Caputi AP, Mannucci C, Russo GA, Gregg E, Puntoni R, et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. Basic Clin Pharmacol Toxicol. 2009; 104 (4): 322-8. DOI: 10.1111/j.1742-7843.2008.00361.x. |
| [46] | Feletou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/endoperoxide receptor (TP): the common villain. J Cardiovasc Pharmacol. 2010; 55 (4): 317-32. DOI: 10.1097/fjc.0b013e3181d8bc8a. |
| [47] | Lopez LR, Guyer KE, Torre IG, Pitts KR, Matsuura E, Ames PR. Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. World J Diabetes. 2014; 5 (2): 115-27. DOI: 10.4239/wjd.v5.i2.115. |
| [48] | Ross R. Atherosclerosis - An Inflammatory Disease. Am Heart J. 1999; 138: S419-20. DOI: 10.1016/S0002-8703(99)70266-8. |
| [49] | Mänttäri M, Manninen V, Koskinen P, Huttunen J, Oksanen E, Tenkanen L, et al. Leukocytes as a coronary risk factor in dyslipidemic male population. Am Heart J. 1992; 123: 873-7. DOI: 10.1016/0002-8703(92)90690-W. |
| [50] | Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol. 1992; 136 (1): 59-70. DOI: 10.1093/oxfordjournals.aje.a116421. |
| [51] | Zalokar JB, Richard JL, Claude JR. Leukocyte count, smoking, and myocardial infarction. N Engl J Med. 1981; 304 (8): 465-8. DOI: 10.1056/NEJM198102193040806. |
| [52] | Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997; 96 (4): 1102-8. DOI: 10.1161/01.cir.96.4.1102. |
| [53] | Brown D, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol. 2001; 54: 316-22. DOI: 10.1016/s0895-4356(00)00296-1. |
| [54] | Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001; 87 (5): 636-9, A10. DOI: 10.1016/s0002-9149(00)01444-2. |
| [55] | Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol. 2001; 154 (8): 758-64. DOI: 10.1093/aje/154.8.758. |
| [56] | Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004; 44 (10): 1945-56. DOI: 10.1016/j.jacc.2004.07.056. |
| [57] | Madjid M, Fatemi O. Components of the Complete Blood Count as Risk Predictors for Coronary Heart Disease In-Depth Review and Update. Tex Heart Inst J. 2013; 40: 17-29. |
| [58] | Hisamatsu T, Miura K, Arima H, Kadota A, Kadowaki S, Torii S, et al. Smoking, Smoking Cessation, and Measures of Subclinical Atherosclerosis in Multiple Vascular Beds in Japanese Men. J Am Heart Assoc. 2016; 5 (9). DOI: 10.1161/JAHA.116.003738. |
| [59] | Kianoush S, Yakoob MY, Al-Rifai M, DeFilippis AP, Bittencourt MS, Duncan BB, et al. Associations of Cigarette Smoking With Subclinical Inflammation and Atherosclerosis: ELSA-Brasil (The Brazilian Longitudinal Study of Adult Health). J Am Heart Assoc. 2017; 6 (6). DOI: 10.1161/JAHA.116.005088. |
| [60] | Conklin DJ, Schick S, Blaha MJ, Carll A, DeFilippis A, Ganz P, et al. Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation. Am J Physiol Heart Circ Physiol. 2019; 316 (4): H801-H27. DOI: 10.1152/ajpheart.00591.2018. |
| [61] | Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010; 138 (3): 682-92. DOI: 10.1378/chest.09-2090. |
| [62] | Scherer G. Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review. Regul Toxicol Pharmacol. 2018; 94: 203-33. DOI: 10.1016/j.yrtph.2018.02.002. |
| [63] | Milne G, Musiek E, Morrow J. F2-Isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers. 2005; 10 Suppl 1: S10-23. DOI: 10.1080/13547500500216546. |
| [64] | Yuan JM, Butler LM, Stepanov I, Hecht SS. Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer. Cancer Res. 2014; 74 (2): 401-11. DOI: 10.1158/0008-5472.CAN-13-3178. |
| [65] | Hecht S, Murphy S, Stepanov I, Nelson H, Yuan J-M. Tobacco Smoke Biomarkers and Cancer Risk Among Male Smokers in the Shanghai Cohort Study. Cancer Lett. 2012; 334 (1): 34-8. DOI: 10.1016/j.canlet.2012.07.016. |
| [66] | Xue J, Yang S, Seng S. Mechanisms of Cancer Induction by Tobacco-Specific NNK and NNN. Cancers (Basel). 2014; 6 (2): 1138-56. DOI: 10.3390/cancers6021138. |
| [67] | Gale N, McEwan M, Eldridge AC, Sherwood N, Bowen E, McDermott S, et al. A randomised, controlled, two-Centre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional cigarette to a tobacco heating product. BMC Public Health. 2017; 17 (1): 673. DOI: 10.1186/s12889-017-4678-9. |
| [68] | Rögner N, Hagedorn H-W, Scherer G, Scherer M, Pluym N. A Sensitive LC–MS/MS Method for the Quantification of 3-Hydroxybenzo[a]pyrene in Urine-Exposure Assessment in Smokers and Users of Potentially Reduced-Risk Products. Separations. 2021; 8 (10): 171. DOI: 10.3390/separations8100171. |
| [69] | Sterz K, Scherer G, Ecker J. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids. J Lipid Res. 2012; 53 (5): 1026-36. DOI: 10.1194/jlr.D023739. |
| [70] | Angerer J. Carboxyhemoglobin [Biomonitoring Methods, 1985]. The MAK-Collection for Occupational Health and Safety. p. 93-105. |
| [71] | Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200 (8): e70-e88. DOI: 10.1164/rccm.201908-1590ST. |
| [72] | Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993; 2 (3): 217-27. DOI: 10.1002/hec.4730020305. |
| [73] | Scherer G, Newland K, Papadopoulou E, Minet E. A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4-aminobiphenyl in smokers. Biomarkers. 2014; 19 (4): 291-301. DOI: 10.3109/1354750X.2014.910271. |
| [74] | Haswell L, Papadopoulou E, Newland N, Shepperd C, Lowe F. A cross-sectional analysis of candidate biomarkers of biological effect in smokers, never-smokers and ex-smokers. Biomarkers. 2014; 19 (5): 356-67. DOI: 10.3109/1354750X.2014.912354. |
| [75] | Lorkiewicz P, Riggs DW, Keith RJ, Conklin DJ, Xie Z, Sutaria S, et al. Comparison of Urinary Biomarkers of Exposure in Humans Using Electronic Cigarettes, Combustible Cigarettes, and Smokeless Tobacco. Nicotine Tob Res. 2019; 21 (9): 1228-38. DOI: 10.1093/ntr/nty089. |
| [76] | Round EK, Chen P, Taylor AK, Schmidt E. Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum. Nicotine Tob Res. 2019; 21 (9): 1239-47. DOI: 10.1093/ntr/nty140. |
| [77] | Cohen G, Goldenson NI, Bailey P, Chan S, Shiffman S. Changes in Biomarkers of Cigarette Smoke Exposure After 6 Days of Switching Exclusively or Partially to Use of the JUUL System with Two Nicotine Concentrations: A Randomized Controlled Confinement Study in Adult Smokers. Nicotine Tob Res. 2021. DOI: 10.1093/ntr/ntab134. |
| [78] | Oliveri D, Liang Q, Sarkar M. Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers. Nicotine Tob Res. 2019; 22 (7): 1114-22. DOI: 10.1093/ntr/ntz185. |
| [79] | Christensen CH, Chang JT, Rostron BL, Hammad HT, van Bemmel DM, Del Valle-Pinero AY, et al. Biomarkers of Inflammation and Oxidative Stress Among Adult Former Smoker, Current E-Cigarette Users Results from Wave 1 PATH Study. Cancer Epidemiol Biomarkers Prev. 2021; 30 (10): 1947-55. DOI: 10.1158/1055-9965.Epi-21-0140. |
| [80] | Gale N, McEwan M, Camacho OM, Hardie G, Proctor CJ, Murphy J. Changes in biomarkers after 180 days of tobacco heating product use: a randomised trial. Intern Emerg Med. 2021. DOI: 10.1007/s11739-021-02798-6. |
| [81] | Beatrice F, Massaro G. Exhaled Carbon Monoxide Levels in Forty Resistant to Cessation Male Smokers after Six Months of Full Switch to Electronic Cigarettes (e-Cigs) or to A Tobacco Heating Systems (THS). Int J Environ Res Public Health. 2019; 16 (20). DOI: 10.3390/ijerph16203916. |
| [82] | Molino A, Fuschillo S, Mosella M, Accardo M, Guida P, Motta A, et al. Comparison of three different exhaled nitric oxide analyzers in chronic respiratory disorders. J Breath Res. 2019; 13 (2): 021002. DOI: 10.1088/1752-7163/ab0167. |
| [83] | Tailor H, Mackie I, Mellick A, Machin S. Evaluation of the Sysmex XN-550, a Novel Compact Haematology analyser from the XN-L® series, compared to the XN-20 system. Int J Lab Hematol. 2017; 39 (6): 585-9. DOI: https://doi.org/10.1111/ijlh.12701. |
| [84] | Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-65. DOI: 10.1164/rccm.201204-0596PP. |
| [85] | Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008; 21 (2): 93-111. DOI: 10.1016/j.echo.2007.11.011. |
APA Style
Nathan Gale, Linsey Ellen Haswell, Michael McEwan, David Azzopardi, Jesse Thissen, et al. (2022). Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol. Journal of Health and Environmental Research, 8(2), 116-127. https://doi.org/10.11648/j.jher.20220802.17
ACS Style
Nathan Gale; Linsey Ellen Haswell; Michael McEwan; David Azzopardi; Jesse Thissen, et al. Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol. J. Health Environ. Res. 2022, 8(2), 116-127. doi: 10.11648/j.jher.20220802.17
AMA Style
Nathan Gale, Linsey Ellen Haswell, Michael McEwan, David Azzopardi, Jesse Thissen, et al. Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol. J Health Environ Res. 2022;8(2):116-127. doi: 10.11648/j.jher.20220802.17
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jher.20220802.17,
author = {Nathan Gale and Linsey Ellen Haswell and Michael McEwan and David Azzopardi and Jesse Thissen and George Hardie},
title = {Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol},
journal = {Journal of Health and Environmental Research},
volume = {8},
number = {2},
pages = {116-127},
doi = {10.11648/j.jher.20220802.17},
url = {https://doi.org/10.11648/j.jher.20220802.17},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jher.20220802.17},
abstract = {Despite public health efforts to reduce the health burden of cigarettes by encouraging smoking cessation, a proportion of smokers remain unwilling to quit. A shift from smoking cessation to tobacco harm reduction, based on smokers switching completely to potentially less harmful products such as electronic cigarettes (ECs), has been proposed as an alternative strategy. This is a single-centre, cross-sectional confinement study, involving healthy exclusive Vuse EC users and current, former, or never-smokers. Exclusive EC use and smoking status will be confirmed by urinary cotinine and exhaled carbon monoxide levels. Participants will be confined for 24 hours, during which they will use their usual product (EC or cigarette) as normal. Biomarkers of exposure and potential harm will be analysed in 24-hour urine and blood and compliance will be measured using N-(2-cyanoethyl)valine. The primary objective is to quantitatively assess differences between EC users and current smokers in urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and 8-epi-prostaglandin F2α Type III, exhaled nitric oxide, and carboxyhaemoglobin, white blood cell count, soluble intercellular adhesion molecule-1, and high-density lipoprotein. Secondary objectives are to quantitatively assess differences between EC users and current smokers in selected urinary biomarkers of tobacco exposure, 11-dehydrothromboxane B2, forced expiratory volume in 1 second as a percentage of predicted, carotid intima-media thickness and a quality of life questionnaire. Endpoints will also be compared between EC users and former and never-smokers. The results of this study are anticipated to add to the current knowledge about the role of ECs in tobacco harm reduction.},
year = {2022}
}
TY - JOUR T1 - Biomarkers of Exposure and Potential Harm in Exclusive Users of Electronic Cigarettes and Current, Former and Never-Smokers: A Cross-Sectional Study Protocol AU - Nathan Gale AU - Linsey Ellen Haswell AU - Michael McEwan AU - David Azzopardi AU - Jesse Thissen AU - George Hardie Y1 - 2022/05/26 PY - 2022 N1 - https://doi.org/10.11648/j.jher.20220802.17 DO - 10.11648/j.jher.20220802.17 T2 - Journal of Health and Environmental Research JF - Journal of Health and Environmental Research JO - Journal of Health and Environmental Research SP - 116 EP - 127 PB - Science Publishing Group SN - 2472-3592 UR - https://doi.org/10.11648/j.jher.20220802.17 AB - Despite public health efforts to reduce the health burden of cigarettes by encouraging smoking cessation, a proportion of smokers remain unwilling to quit. A shift from smoking cessation to tobacco harm reduction, based on smokers switching completely to potentially less harmful products such as electronic cigarettes (ECs), has been proposed as an alternative strategy. This is a single-centre, cross-sectional confinement study, involving healthy exclusive Vuse EC users and current, former, or never-smokers. Exclusive EC use and smoking status will be confirmed by urinary cotinine and exhaled carbon monoxide levels. Participants will be confined for 24 hours, during which they will use their usual product (EC or cigarette) as normal. Biomarkers of exposure and potential harm will be analysed in 24-hour urine and blood and compliance will be measured using N-(2-cyanoethyl)valine. The primary objective is to quantitatively assess differences between EC users and current smokers in urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and 8-epi-prostaglandin F2α Type III, exhaled nitric oxide, and carboxyhaemoglobin, white blood cell count, soluble intercellular adhesion molecule-1, and high-density lipoprotein. Secondary objectives are to quantitatively assess differences between EC users and current smokers in selected urinary biomarkers of tobacco exposure, 11-dehydrothromboxane B2, forced expiratory volume in 1 second as a percentage of predicted, carotid intima-media thickness and a quality of life questionnaire. Endpoints will also be compared between EC users and former and never-smokers. The results of this study are anticipated to add to the current knowledge about the role of ECs in tobacco harm reduction. VL - 8 IS - 2 ER -
Email: